Document is current
Any future updates will be listed below
-
Authors
Uzawa, Akiyuki
Suzuki, Shigeaki
Kuwabara, Satoshi
Akamine, Hiroyuki
Onishi, Yosuke
Yasuda, Manato
Ozawa, Yukiko
Kawaguchi, Naoki
Kubota, Tomoya
Takahashi, Masanori P.
Suzuki, Yasushi
Watanabe, Genya
Kimura, Takashi
Sugimoto, Takamichi
Samukawa, Makoto
Minami, Naoya
Masuda, Masayuki
Konno, Shingo
Nagane, Yuriko
Utsugisawa, Kimiaki
-
Funding
Funding for this research was provided by:
Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan (20FC1030, 20FC1030)
- License Information
-
More Information
Article History
Received: 30 December 2023
Accepted: 18 April 2024
First Online: 25 April 2024
Declarations
:
: This study was approved by the ethics committee of each neurological center (Institutional Ethical Review Board No. R3-1 at Hanamaki General Hospital, the primary investigating institute) and written informed consent was obtained from all study participants. The authors have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations.
: Not applicable.
: Akiyuki Uzawa has received honoraria from Alexion Pharmaceuticals and Argenx. Shigeaki Suzuki received speakers’ fees from Alexion Pharmaceuticals, the Japan Blood Products Organization, Asahi Kasei Medical, and Argenx, and participated in an advisory board meeting of Alexion Pharmaceuticals and Argenx. Satoshi Kuwabara has received Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan (20FC1030) and honoraria from CSL Behring. T. Kubota reports receiving an honorarium for lectures from Alexon Pharmaceuticals, Argenx, and UCB Pharma. Masanori. P. Takahashi reports unrestricted research grants from Japan Blood Products Organization, Astellas Pharma, Mitsubishi Tanabe Pharma, and Pfizer, outside the submitted work, and has served as a paid Consultant for Alexion, Argenx, Sanofi, and UCB Pharma and received an honorarium for lectures from Argenx, Alexion Pharmaceuticals, and UCB Pharma. Masayuki Masuda has received speaker honoraria from Argenx, Asahi Kasei Medical, UCB Pharma, and Alexion Pharmaceutical, and participated in an advisory board meeting of Alexion Pharmaceutical and Argenx. Kimiaki Utsugisawa has served as a paid Consultant for UCB Pharma, Janssen Pharma, Horizon Therapeutics (Viela Bio), Chugai Pharma, Hanall BioPharma, and Mitsubishi Tanabe Pharma and has received speaker honoraria from Argenx, Alexion Pharmaceuticals, UCB Pharma, and the Japan Blood Products Organization. Other authors declare no financial or other conflicts of interest.
